Horizon Discovery plcの債務/株式
Horizon Discovery plcの債務/株式は何ですか。
Horizon Discovery Group plcの債務/株式は0.22です。
債務/株式の定義は何ですか。
負債比率は、株主資本と企業資産の融資に使用される負債の相対的割合を示す財務比率です。
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
LSEのセクタHealth Careにおける債務/株式の企業と比べるHorizon Discovery plc
Horizon Discovery plcは何をしますか。
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Horizon Discovery plcと類似の債務/株式
- Vectura Plcの債務/株式は0.22です。
- Kitex Garmentsの債務/株式は0.22です。
- Immuronの債務/株式は0.22です。
- JH Educational Technology INCの債務/株式は0.22です。
- Silver Viper Mineralsの債務/株式は0.22です。
- Maxicityの債務/株式は0.22です。
- Horizon Discovery plcの債務/株式は0.22です。
- Bajaj Autoの債務/株式は0.22です。
- Gracoの債務/株式は0.22です。
- Mi Ming Martの債務/株式は0.22です。
- KuangChi Scienceの債務/株式は0.22です。
- Singular Health Ltdの債務/株式は0.22です。
- Strong Petrochemicalの債務/株式は0.22です。